| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Additional Infomation |
Menadione-4 is a menadione compound with four all-trans isoprene units in its side chain. It plays a role in maintaining bone density, acting as a metabolite, an antioxidant, an anti-inflammatory agent, and a neuroprotective agent. Menadione-4 has been used in clinical trials for the treatment of diabetes, osteoporosis, prediabetes, and hepatocellular carcinoma. Menadione-4 is a menadione compound and a form of vitamin K2, possessing potential antitumor activity. Menadione-4 may exert its effects by modulating the signaling of certain tyrosine kinases, thereby affecting multiple transcription factors, including c-myc and c-fos. This drug inhibits tumor cell growth by inducing apoptosis and cell cycle arrest.
|
|---|
| Molecular Formula |
C20H28O
|
|---|---|
| Molecular Weight |
284.44
|
| Exact Mass |
444.302
|
| CAS # |
11032-49-8
|
| Related CAS # |
Menaquinone-4;863-61-6
|
| PubChem CID |
5282367
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
570.6±50.0 °C at 760 mmHg
|
| Melting Point |
54 °C
|
| Flash Point |
208.3±27.1 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.539
|
| LogP |
10.94
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
33
|
| Complexity |
855
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CC/C=C(\C)/CC/C=C(\C)/CCC=C(C)C
|
| InChi Key |
DKHGMERMDICWDU-GHDNBGIDSA-N
|
| InChi Code |
InChI=1S/C31H40O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,12,14,16,18-20H,9-11,13,15,17,21H2,1-6H3/b23-14+,24-16+,25-20+
|
| Chemical Name |
2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]naphthalene-1,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (175.78 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (8.79 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (8.79 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5157 mL | 17.5784 mL | 35.1568 mL | |
| 5 mM | 0.7031 mL | 3.5157 mL | 7.0314 mL | |
| 10 mM | 0.3516 mL | 1.7578 mL | 3.5157 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT06817512
Conditions:Ischemic StrokeLink: https://clinicaltrials.gov/ct2/show/NCT05500443
Conditions:Coronary Artery DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT05547750
Conditions:Nocturnal Leg Cramps
Title:Pilot Study of Vitamin K2 (MK-7) and Vitamin D3 Supplementation and the Effects on PASC Symptomatology and Inflammatory Biomarkers
Status:Completed
updateDate:2024-09-27
Ctid:NCT05356936
Link: https://clinicaltrials.gov/ct2/show/NCT05356936
Conditions:Post-acute COVID-19 SyndromeLink: https://clinicaltrials.gov/ct2/show/NCT05995522
Conditions:Overweight and Obesity|Cardiometabolic Risk FactorsLink: https://clinicaltrials.gov/ct2/show/NCT04676958
Conditions:Inflammation|Oxidative Stress|Vitamin K|Exercise|Strength|RecoveryLink: https://clinicaltrials.gov/ct2/show/NCT05375630
Conditions:Diabete Type 2Link: https://clinicaltrials.gov/ct2/show/NCT05675163
Conditions:Oxidative Stress|InflammationLink: https://clinicaltrials.gov/ct2/show/NCT05161975
Conditions:Muscle Atrophy|CachexiaLink: https://clinicaltrials.gov/ct2/show/NCT04429035
Conditions:Aortic Valve Stenosis|Aortic Valve Calcification|Mitral Annular Calcification|Mitral Valve Calcification|Mitral Valve StenosisLink: https://clinicaltrials.gov/ct2/show/NCT04477811
Conditions:End Stage Renal Disease on DialysisLink: https://clinicaltrials.gov/ct2/show/NCT03897660
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT02976246
Conditions:Vitamin K Supplementation|Endstage Renal Disease|Cardiovascular Disease|Bone DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT04382027
Conditions:HealthyLink: https://clinicaltrials.gov/ct2/show/NCT01232647
Conditions:Post-menopausal OsteoporosisLink: https://clinicaltrials.gov/ct2/show/NCT03311321
Conditions:Cardiovascular Diseases|Chronic Kidney Disease Stage 3|Chronic Kidney Disease Stage 4|Chronic Kidney Disease Stage 5|Vitamin K Deficiency|HemodialysisLink: https://clinicaltrials.gov/ct2/show/NCT02959762
Conditions:Obesity|Insulin Resistance|Obesity in Diabetes|Nutritional and Metabolic Diseases|Hyperlipidemia|Hyperglycemia|Cardiovascular DiseasesLink: https://clinicaltrials.gov/ct2/show/NCT01972113
Conditions:Obesity|Insulin Resistance|Insulin Sensitivity|Prediabetes|Dyslipidemia|DiabetesLink: https://clinicaltrials.gov/ct2/show/NCT04145492
Conditions:End Stage Renal DiseaseLink: https://clinicaltrials.gov/ct2/show/NCT02610933
Conditions:Vascular CalcificationLink: https://clinicaltrials.gov/ct2/show/NCT00548509
Conditions:OsteoporosisLink: https://clinicaltrials.gov/ct2/show/NCT02917525
Conditions:Aortic Valve Stenosis|Bicuspid Aortic ValveLink: https://clinicaltrials.gov/ct2/show/NCT02517580
Conditions:Arterial Stiffness|Vitamin K2 DeficiencyLink: https://clinicaltrials.gov/ct2/show/NCT00062595
Conditions:OsteoporosisLink: https://clinicaltrials.gov/ct2/show/NCT00165698
Conditions:Postmenopausal OsteoporosisLink: https://clinicaltrials.gov/ct2/show/NCT01923012
Conditions:Carotid Disease|AtherosclerosisLink: https://clinicaltrials.gov/ct2/show/NCT01533441
Conditions:ThrombosisLink: https://clinicaltrials.gov/ct2/show/NCT01638182
Conditions:Bone Health|Vascular HealthLink: https://clinicaltrials.gov/ct2/show/NCT00960973
Conditions:Diabetes|Prediabetic StateLink: https://clinicaltrials.gov/ct2/show/NCT01194778
Conditions:Carboxylation Level|Vitamin K-dependent ProteinsLink: https://clinicaltrials.gov/ct2/show/NCT01101698
Conditions:Kidney Diseases|Coronary Artery CalcificationLink: https://clinicaltrials.gov/ct2/show/NCT00165607
Conditions:OsteoporosisLink: https://clinicaltrials.gov/ct2/show/NCT00165633
Conditions:Hepatocellular CarcinomaProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
